ZB

Zura Bio Limited

ZURA·NASDAQ

$3.83

-6.5%
HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$249.36M
EPS-1.0600
P/E Ratio-3.62
Earnings Date08/13/2026

zura

Research Development Expenses

Last Annual Value

42.08M

3-Year CAGR

21%

5-Year CAGR

%

10-Year CAGR

%

ZB

Zura Bio Limited Competitors Analysis of research-development-expenses

ZURA · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
42.08M
-1.5%N/AN/A 
73.70M
14.1%7.6%N/A
109.44M
-0.8%15.9%N/A
3.64M
33.4%40.1%N/A
16.02M
-12.6%-5.6%-2.1%
142.27M
12.5%31.7%N/A
48.94M
121.9%N/AN/A
42.05M
0.3%9.6%N/A
68.61M
-11.2%4.8%N/A
39.05M
25.5%15.1%N/A
64.81M
9.8%-1.1%7.0%
ZB

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.835, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

Intrinsic Value
Current Price: $3.835